Search results
Showing 1 to 15 of 61 results for warfarin
patients according to NICE guidelines regarding anticoagulation. Patients on warfarin need tight control over their time in range (TIR)...
The effect of COVID-19 related lockdown on patients taking warfarin
January 2021 Patients on warfarin need to be within a therapeutic range in order to remain safe We looked
aim of this project was to capture the prevalence of patients with AF on warfarin for stroke control exhibiting poor anticoagulation...
Acute upper gastrointestinal bleeding in over 16s: management (CG141)
This guideline covers how upper gastrointestinal bleeding can be effectively managed in adults and young people aged 16 years and older. It aims to identify which diagnostic and therapeutic steps are useful so hospitals can develop a structure in which clinical teams can deliver an optimum service for people who develop this condition.
View recommendations for CG141Show all sections
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
View recommendations for TA275Show all sections
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults.
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.